Medicine and Dentistry
Acute Myeloid Leukemia
87%
Overall Survival
44%
Myelodysplastic Syndrome
30%
Hematopoietic Stem Cell
30%
Decitabine
29%
Lenalidomide
26%
Autologous Stem Cell Transplantation
25%
Cell Transplantation
21%
Diffuse Large B-Cell Lymphoma
21%
Rituximab
17%
Hematopoiesis
17%
Myelodysplastic Syndrome
17%
Azacitidine
17%
Neoplasm
16%
Cohort Analysis
15%
Arm
15%
Cancer Cell
14%
Hazard Ratio
14%
Leukemia
12%
Peripheral T-Cell Lymphoma
11%
Acute Myelogenous Leukemia
11%
Angioimmunoblastic T-Cell Lymphoma
11%
In Vitro
11%
Positron Emission Tomography-Computed Tomography
10%
Platelet
10%
Population
10%
Posttransplant Lymphoproliferative Disease
10%
Quality of Life
10%
T Cell
10%
Disease
10%
Gene Expression Profiling
9%
Anemia
9%
Progression Free Survival
9%
Leukemia Cell
8%
Hematopoietic Stem Cell
8%
Phagocytosis
8%
Malignant Neoplasm
8%
Programmed Cell Death
7%
Multiple Myeloma
7%
Mitochondrial Respiration
7%
Cancer Registry
7%
Myeloid Malignancy
7%
Clinical Trial
7%
Pemphigus vulgaris
7%
Autophagy
7%
Hypomethylating Agent
6%
Graft Versus Host Reaction
6%
Minimal Residual Disease
6%
Scoring System
6%
Flow Cytometry
6%
Immunology and Microbiology
Myeloid
100%
Hematopoietic Cell
34%
B Cell
30%
T Cell
28%
Overall Survival
26%
Cell Transplantation
24%
Hematopoiesis
21%
CD34
20%
CD47
19%
Cancer Cell
17%
Autologous Stem Cell Transplantation
16%
Rituximab
15%
Phagocytosis
14%
Population
14%
Macrophage
13%
Stem Cell
13%
Arm
11%
Antineoplastic Activity
11%
Gene Expression Profiling
10%
Hematopoietic Stem Cell
9%
Transplant Procedure
9%
Graft-Versus-Host Disease
9%
Cytotoxicity
9%
Leukemia Cell
8%
Lenalidomide
8%
CD20
8%
Acute Graft Versus Host Disease
8%
T Cell Receptor
8%
Allogeneic Hematopoietic Stem Cell Transplantation
7%
Tumor Volume
7%
Clonal Evolution
7%
Lymphocyte
7%
Mitochondrial Respiration
7%
Pemphigus vulgaris
7%
Bispecific Antibody
7%
Ecalectin
7%
Drug Megadose
7%
Hematopoietic Stem Cell Transplantation
6%
Blood Plasma
6%
Monospecific Antibody
6%
Tumor Cell
5%
Leukocyte Count
5%
Cell Membrane
5%
Conditioning
5%
Cyclophosphamide
5%
Lineages
5%
Natural Killer Cell
5%
Keyphrases
Acute Myeloid Leukemia
58%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
28%
Overall Survival
18%
Older Patients
18%
Decitabine
17%
Intensive Chemotherapy
16%
Netherlands
15%
Improved Outcomes
12%
Leukemia Risk
10%
Hazard Ratio
10%
Health-related Quality of Life
10%
Myelodysplastic Syndrome
10%
Confidence Interval
10%
Leukemia Patients
9%
Anemia
9%
Lenalidomide
8%
Angioimmunoblastic T-cell Lymphoma
8%
Chemotherapy
8%
Rituximab
8%
High Risk
8%
Cytopenia
7%
High-risk Myelodysplastic Syndrome
7%
Cytarabine
7%
Azacitidine
7%
Non-myeloablative Transplantation
7%
Nonmyeloablative
7%
Pemphigus Vulgaris
7%
High-risk MDS
7%
Clonal Hematopoiesis
7%
Comorbidity
7%
Treatment Outcome
7%
Ara-C
7%
Graft-versus-host Disease (GvHD)
6%
Aging
6%
B Cells
5%
Leukemia
5%
Cancer Registry
5%
Prospective Randomized Trial
5%
Peripheral T-cell Lymphoma
5%